Profound Medical Corp. (PROF): TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
Profound Medical Corp. (PROF) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”
How this was made
The 30-second read
Why it matters
The new clinical and technical data provide the first public, peer‑reviewed evidence of TULSA‑PRO's efficacy and platform flexibility, which could lift investor confidence and support future financing or partnership opportunities.
Market read
The filing introduces fresh clinical evidence that may improve PROF's valuation and influence the prostate‑cancer med‑tech landscape.
What to watch
Potential reimbursement challenges and the need for larger, multi‑center trials could delay market adoption.
Background
Profound Medical (NASDAQ:PROF) uses the TULSA‑PRO system for MRI‑guided focal therapy of localized prostate cancer. The company filed an 8‑K to disclose recent conference abstracts.
Ticker impact
Profound Medical filed an 8‑K announcing five new abstracts that provide clinical trial results, real‑world registry data and technical validation for its TULSA‑PRO prostate cancer therapy platform.
likely modest upside as investors price in stronger clinical evidence and expanded platform options
First public disclosure of multiple peer‑reviewed abstracts, including a randomized trial showing superior functional outcomes versus surgery, represents material new information for a small‑cap med‑tech company.
Market effects
Strengthens the med‑tech prostate‑cancer segment and may prompt competitors to accelerate their own trials.
Primarily U.S. biotech investors; limited immediate effect on broader markets.
Adds to global evidence base for focal therapy, but impact confined to niche therapeutic market.
Counterpoint
The abstracts are early‑stage data; without FDA approval the results may not translate into commercial revenue soon.
Key entities
- companyProfound Medical Corp.
Developer of the TULSA‑PRO MRI‑guided prostate cancer therapy system.
- institutionMayo Clinic
Conducted real‑world studies on TULSA‑PRO outcomes.
- clinical_trialCAPTAIN Trial
Randomized study comparing TULSA‑PRO to robotic radical prostatectomy.
